Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

Inclusion Criteria:

• Diagnosis of acute pancreatitis (AP) 0-90 days prior to enrollment

• Participant fully understands and is able to participate in all aspects of thestudy, including providing informed consent, completion of case report forms,telephone interviews, metabolic testing, and planned longitudinal follow-ups

Exclusion Criteria:

• Diagnosis of definite chronic pancreatitis (CP) at enrollment (see also studydefinitions) based on either of the following criteria met by computed tomography (CT) scan (including non-contrast enhanced) or Magnetic Resonance Imaging (MRI) orMagnetic Resonance Cholangiopancreatography (MRCP): (a) Parenchymal or ductalcalcifications on CT scan (after excluding the possibility that calcifications arevascular); (b) Intraductal filling defects suggestive of calcifications on MRIand/or MRCP

• Potential participants with post-endoscopic retrograde cholangiopancreatography (ERCP) AP who are hospitalized for <48 hours.

• Prior (i.e., before enrollment) direct endoscopic necrosectomy of the pancreas orpercutaneous necrosectomy or drainage of necrotic collection(s). Participants whorequire this during follow-up will remain in the study

• Pancreatic tumors, including ductal adenocarcinoma, neuroendocrine tumors, andmetastasis

• Confirmed or suspected cystic tumor associated with main pancreatic duct dilation,or believed to be the cause of AP (in the site-PI's judgement).

• Prior pancreatic surgery, including, but not limited to: distal pancreatectomy,pancreaticoduodenectomy, pancreatic necrosectomy, Frey procedure.

• Use of disallowed concomitant medications within 30 days prior to enrollment. Acomprehensive list of disallowed medications will be included and routinely updatedin the study's Manual of Procedures

• Severe systemic illness that in the judgement of the investigative team willconfound outcome assessments of diabetes mellitus and immunological outcomes or poseadditional risk for harms, including: history of solid organ transplant, acquiredimmunodeficiency syndrome (AIDS), active treatment for cancer (except non-melanomaskin cancer) within 12 months prior to enrollment, chronic kidney disease withestimated glomerular filtration rate (eGFR) < 30 or on dialysis prior to AP, anddecompensated cirrhosis (based on imaging or biopsy), or any other medical conditionthat in the opinion of the site-PI carries a life expectancy of <12 months

• Known pregnancy at the time of enrollment. Participants who become pregnant duringfollow-up will remain in the study, but may have modified study assessments forsafety as detailed in the Manual of Procedures

• Incarceration

• Any other condition or factor that would compromise the participant's safety or thescientific integrity of the study